<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infantile epileptic spasms syndrome: Management and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infantile epileptic spasms syndrome: Management and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Infantile epileptic spasms syndrome: Management and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Danielle S Takacs, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Akshat Katyayan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION AND TERMINOLOGY</span><span class="headingEndMark"> — </span>Infantile spasms represent an age-specific epileptic disorder of infancy and early childhood. Children with infantile spasms typically exhibit epileptic spasms along with the electroencephalographic (EEG) pattern known as hypsarhythmia.</p><p>The International League Against Epilepsy has proposed the term "infantile epileptic spasms syndrome (IESS)" to encompass infants presenting with epileptic spasms, with or without fulfilling all of the criteria for West syndrome, which is a triad of epileptic spasms, arrest or regression of psychomotor development, and hypsarhythmia [<a href="#rid1">1,2</a>]. Infants with IESS may often lack one of these three criteria, but management recommendations remain the same. </p><p>The management and prognosis of infantile spasms are reviewed here. The etiology and pathogenesis, clinical features, and diagnosis of this disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6163.html" rel="external">"Infantile epileptic spasms syndrome: Etiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/6145.html" rel="external">"Infantile epileptic spasms syndrome: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H3956269978"><span class="h1">CHOOSING INITIAL THERAPY</span><span class="headingEndMark"> — </span>The major options for treatment of infantile epileptic spasms syndrome (IESS), also known as "infantile spasms," are hormonal therapy (ie, adrenocorticotropin hormone [ACTH] in the form of <a class="drug drug_pediatric" data-topicid="13181" href="/z/d/drug information/13181.html" rel="external">corticotropin injection gel</a>, cosyntropin, tetracosactide, and oral glucocorticoids) and/or <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a>. Initial combination treatment with both hormonal therapy and vigabatrin may be more effective than hormonal therapy alone and is the standard of first-line management in many centers or protocols [<a href="#rid3">3</a>]. (See <a class="local">'Combination therapy'</a> below.)</p><p class="headingAnchor" id="H3372483981"><span class="h2">Urgency of treatment</span><span class="headingEndMark"> — </span>Treatment for infantile spasms should be started urgently (within three days or less) once the diagnosis is made. The importance of urgent treatment initiation has been well recognized, given particular evidence for improved developmental outcomes associated with early recognition and implementation of therapy [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2186166097"><span class="h2">Hormonal therapy for patients without tuberous sclerosis</span><span class="headingEndMark"> — </span>The mainstay of medical treatment for most patients with infantile spasms (excepting those with tuberous sclerosis complex) is hormonal therapy with <a class="drug drug_pediatric" data-topicid="13181" href="/z/d/drug information/13181.html" rel="external">corticotropin injection gel</a> (ACTH) or oral glucocorticoids [<a href="#rid5">5-12</a>]. (See <a class="local">'Corticotropin (ACTH)'</a> below.)</p><p>Glucocorticoid hormonal therapy regimens (eg, <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>, <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a>, <a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">methylprednisolone</a>, or <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>) are effective alternatives to corticotropin (ACTH) and are less costly and easier to administer than corticotropin. Historically, corticotropin gel was the preferred hormonal therapy, but high-quality data comparing oral glucocorticoids to corticotropin are lacking, and there is no clear consensus for choosing one or the other. (See <a class="local">'Glucocorticoids'</a> below.)</p><p>With the exception of <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> (see <a class="local">'Vigabatrin'</a> below), antiseizure medications are <strong>not</strong> considered effective as a first-line treatment for infantile spasms. (See <a class="local">'Other antiseizure medications'</a> below.)</p><p class="headingAnchor" id="H1713994012"><span class="h2">Vigabatrin for patients with tuberous sclerosis</span><span class="headingEndMark"> — </span>For infants with tuberous sclerosis complex, <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> is first-line therapy for infantile spasms. (See <a class="local">'Vigabatrin'</a> below and  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Initial ASM therapy'</a>.)</p><p class="headingAnchor" id="H1793550933"><span class="h2">Special patient populations</span><span class="headingEndMark"> — </span>In addition to infants with tuberous sclerosis complex, we sometimes use <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> as initial therapy for infantile spasms (rather than hormonal therapy) in selected infants with special considerations including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac disease</p><p class="bulletIndent1"><span class="glyph">●</span>At high risk of infections</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of cortical dysplasia</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic infantile spasms</p><p></p><p>The ketogenic diet is used to treat infantile spasms in children with pyruvate dehydrogenase deficiency. (See  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy", section on 'Pyruvate dehydrogenase deficiency'</a>.)</p><p><a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">Pyridoxine</a> is first-line treatment for infants with vitamin B6 deficiency or dependency and infantile spasms. (See <a class="local">'Pyridoxine'</a> below.)</p><p class="headingAnchor" id="H961845837"><span class="h2">Hormonal therapy</span><span class="headingEndMark"> — </span>The mainstay of medical treatment for most infants with infantile spasms is hormonal therapy with corticotropin (ACTH) or oral glucocorticoids [<a href="#rid5">5-7</a>].</p><p class="headingAnchor" id="H1253711835"><span class="h3">Corticotropin (ACTH)</span></p><p class="headingAnchor" id="H143071694"><span class="h4">Formulation</span><span class="headingEndMark"> — </span>The ACTH formulation most commonly used in the United States is a natural preparation (<a class="drug drug_pediatric" data-topicid="13181" href="/z/d/drug information/13181.html" rel="external">corticotropin injection gel</a>), given intramuscularly (IM) or subcutaneously, and it is very expensive [<a href="#rid13">13</a>]. This preparation is a mixture of peptides and derivatives and is measured in units.</p><p>A synthetic long-acting corticotropin preparation, cosyntropin (tetracosactide), is available in Canada, Europe, and elsewhere and is measured in milligrams. According to manufacturer data, patients receiving 40 units of natural <a class="drug drug_pediatric" data-topicid="13181" href="/z/d/drug information/13181.html" rel="external">corticotropin injection gel</a> may be converted to 0.5 mg IM every <strong>other</strong> day of cosyntropin depot [<a href="#rid14">14</a>]. Data comparing the natural and synthetic forms are not available, but uncontrolled observations suggest that efficacy is similar [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H143070723"><span class="h4">Dose</span><span class="headingEndMark"> — </span>The optimal dose of <a class="drug drug_pediatric" data-topicid="13181" href="/z/d/drug information/13181.html" rel="external">corticotropin injection gel</a> is often debated.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-dose protocol</strong> – Most centers (and the authors of this topic) utilize a high-dose protocol  (<a class="graphic graphic_table graphicRef134829" href="/z/d/graphic/134829.html" rel="external">table 1</a>), as this is the best-studied dose and typically provides the best short-term response in the authors' clinical experience. The high-dose regimen begins with <a class="drug drug_pediatric" data-topicid="13181" href="/z/d/drug information/13181.html" rel="external">corticotropin injection gel</a> 75 units/m<sup>2</sup> IM twice daily (or 150 units/m<sup>2</sup> IM once daily) for two weeks, followed by a taper over two to four weeks [<a href="#rid17">17-20</a>]. The dosing recommendations from the Pediatric Epilepsy Research Consortium (PERC) can be found in the table  (<a class="graphic graphic_table graphicRef134829" href="/z/d/graphic/134829.html" rel="external">table 1</a>) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-dose therapy</strong> – Two small randomized trials reported that response to low-dose therapy (20 units per day) was comparable to higher doses and resulted in fewer side effects [<a href="#rid21">21,22</a>]. In the larger of the trials, 50 patients with recently diagnosed infantile spasms were randomly assigned to receive high-dose ACTH (150 units/m<sup>2</sup> per day for three weeks, 80 units/m<sup>2</sup> per day for two weeks, 80 units/m<sup>2</sup> every other day for three weeks, 50 units/m<sup>2</sup> every other day for one week, and taper to zero over three weeks) or low-dose ACTH (20 to 30 units per day for two to six weeks, then taper to zero over one week) [<a href="#rid21">21</a>]. The groups were similar in response to treatment (cessation of spasms and disappearance of hypsarhythmia; 50 versus 58 percent) and rate of relapse. Hypertension occurred more often in the high-dose group (31 versus 4 percent); other side effects were similar between groups. Other retrospective studies also confirm the similar efficacy and fewer adverse side effects using lower-dose synthetic ACTH therapy [<a href="#rid15">15,16,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Step-up dosing</strong> – A strategy individualizing therapy to treatment response was evaluated in a multicenter study of 30 patients [<a href="#rid24">24</a>]. Treatment was started with low-dose ACTH (3 units/kg per day) administered for two to three weeks. In patients who did not respond initially, the dose was increased in intervals to a maximum of 12 units/kg per day [<a href="#rid25">25</a>]. Most patients with spasms of unknown etiology and one-half of those with spasms of known etiology responded to low-dose ACTH given over the course of two to three weeks. Side effects were related to dose. Other centers have also reported success with a "step-up" dosing protocol, with even lower initial doses [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Given the advent of data (see <a class="local">'Efficacy of hormonal therapy'</a> below) that have suggested, but not proven, that high-dose <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> regimens are as effective as corticotropin (ACTH), and given considerable reduction in the cost of treatment and ease of administration with oral glucocorticoids, many centers are now routinely using high-dose oral glucocorticoids as initial therapy for infantile spasms.</p><p>A 2015 consensus document from the International League Against Epilepsy (ILAE) concluded that glucocorticoids are probably effective in the short-term control of spasms, but that the optimal preparation, dose, and duration have not been established [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3646765812"><span class="h4">Dose</span><span class="headingEndMark"> — </span>We typically begin treatment with <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> using the regimen recommended by the PERC, which can be found in the table  (<a class="graphic graphic_table graphicRef134829" href="/z/d/graphic/134829.html" rel="external">table 1</a>). Other experts use slightly different dosing from the United Kingdom Infantile Spasms Study (UKISS) [<a href="#rid26">26</a>].</p><p>Adverse effects are generally similar with <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> as with ACTH therapy. (See <a class="local">'Adverse effects of hormonal therapy'</a> below.)</p><p class="headingAnchor" id="H3196490063"><span class="h3">Adverse effects of hormonal therapy</span><span class="headingEndMark"> — </span>Significant adverse effects may occur with ACTH, as they did in 37 and 85 percent of treated patients in two reports [<a href="#rid27">27,28</a>]. Adverse effects include hypertension, immune suppression and infection, electrolyte imbalance, gastrointestinal disturbances, ocular opacities, hypertrophic cardiomyopathy, cerebral atrophy, growth impairment, and adrenal insufficiency [<a href="#rid5">5,21,23,29-34</a>]. Cases of anaphylaxis have been reported [<a href="#rid35">35</a>]. A transient cushingoid appearance, hirsutism, irritability, and sleep disorders also are seen [<a href="#rid27">27</a>]; these changes are reversible upon discontinuation of the drug. Similar adverse effects are associated with glucocorticoid treatment. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>The risk of adverse effects with hormonal therapy is typically increased with prolonged duration of treatment. (See <a class="local">'Duration of initial therapy'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – Hypertension is the most common complication [<a href="#rid29">29</a>]. In one series, hypertension, defined as three consecutive blood pressure measurements greater than the 95th percentile (stage 1) or greater than the 99th percentile (stage 2) for age, sex, and height (which for infants of 10 kg is typically near 100 to 110 mmHg systolic), occurred in 44 percent of patients [<a href="#rid33">33</a>]. Intracranial hemorrhage has been associated with hypertension in this condition [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – In one study, infection related to ACTH occurred in 6 percent of patients [<a href="#rid36">36</a>]. Rarely, death due to sepsis directly attributable to ACTH has been reported [<a href="#rid27">27,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolyte imbalance</strong> – Electrolyte imbalance may depend upon the glucocorticoid dose. Hypokalemic alkalosis occurred in as much as 12 percent of patients on high-dose ACTH [<a href="#rid27">27</a>]. By contrast, no significant electrolyte abnormalities were detected by serial laboratory monitoring during low-dose, short-term hormonal therapy [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritability and sleep disturbance</strong> – Patients with infantile spasms often have increased irritability during treatment and may have disturbed sleep patterns, although these may be caused in part by the underlying disease. Compared with normal infants, total sleep time and the proportion of rapid eye movement (REM) sleep are reduced in infantile spasms [<a href="#rid38">38</a>]. Thus, sleep disturbances may be caused by infantile spasms rather than hormonal therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain atrophy</strong> – Reduced brain size may result from ACTH and glucocorticoid therapy. Ventriculomegaly and increased volume of the subarachnoid space, consistent with cerebral atrophy, have been detected with neuroimaging of patients receiving hormonal treatment for infantile spasms [<a href="#rid29">29,39-42</a>]. These changes may persist after termination of therapy. In a trial comparing ACTH and <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>, cerebral atrophy was detected by CT scan in 62 percent of patients during treatment; changes persisted in 42 percent six weeks after therapy was stopped [<a href="#rid29">29</a>]. Subdural hematoma, resulting from brain shrinkage, may occur, even during administration of low-dose ACTH therapy [<a href="#rid43">43</a>]. These findings are consistent with studies in animals treated with ACTH and glucocorticoids that demonstrate interference with synthesis of brain DNA (deoxyribonucleic acid), RNA (ribonucleic acid), and protein, and reduction in brain size [<a href="#rid44">44,45</a>]. The relationship of the changes in brain volume to long-term neurologic outcome of patients with infantile spasms is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for decreased bone density</strong> – Patients treated with high-dose and prolonged regimens of glucocorticoid therapy may be at risk for reduced bone density later in life [<a href="#rid46">46</a>]; however, there are no studies that indicate whether follow-up is needed to diagnose and treat this condition.</p><p></p><p class="headingAnchor" id="H1105306250"><span class="h3">Monitoring hormonal therapy</span><span class="headingEndMark"> — </span>Monitoring of patients on hormonal therapy with corticotropin or glucocorticoids should include measurement of blood pressure (baseline and once weekly) and serum concentrations of glucose, potassium, and sodium (baseline and every other week). More frequent monitoring and/or intervention is indicated for persistently abnormal results. Infectious contacts should be avoided, and the patient should be observed closely and treated promptly for signs of infection [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H2731260506"><span class="h3">Efficacy of hormonal therapy</span><span class="headingEndMark"> — </span>Several meta-analyses of randomized trials comparing the effectiveness of ACTH (corticotropin or tetracosactide) with oral glucocorticoids have found no difference between the two forms of hormonal treatment for outcomes including cessation of infantile spasms, hypsarhythmia resolution, adverse effects, relapse rate, or subsequent development of epilepsy [<a href="#rid48">48-50</a>].</p><p>Data from the National Infantile Spasms Consortium prospective multicenter cohort study also support corticotropin and oral glucocorticoids as effective first-line treatments [<a href="#rid51">51</a>]. Among 423 infants two months to two years of age with new-onset infantile spasms, 190 were treated with corticotropin, 95 with glucocorticoids (<a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> or <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a>), 86 with <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a>, and 51 with nonstandard therapies. Propensity score weighting was used to reduce the effects of selection bias. Freedom from treatment failure (defined as freedom from infantile spasms beginning within 30 days of the start of treatment, and no second treatment prescribed within 60 days) varied by treatment: ACTH, 46 percent; oral glucocorticoids, 44 percent; vigabatrin, 37 percent; nonstandard therapies, 8 percent. In the vigabatrin group, freedom from treatment failure was higher among infants with tuberous sclerosis complex (13 of 21, 62 percent) compared with other infants (19 of 65, 29 percent).</p><p>Of note, conclusions have been limited by the overall poor methodology and small size of most of the available clinical trials and studies. Lack of adherence to standardized case definitions and outcome measures is one problem with many studies. Another is that inclusion of a control group is impracticable, as the natural history of the disease is that clinical spasms subside and EEG patterns evolve without therapy, yet many clinicians would be reluctant not to treat, particularly since there are observational data suggesting that delayed therapy may worsen prognosis. As a result, questions remain regarding the optimal drug, dose, and duration of therapy.</p><p class="headingAnchor" id="H7423890"><span class="h3">Mechanism of hormonal therapy</span><span class="headingEndMark"> — </span>The precise mechanism of action of ACTH and glucocorticoids is not known. Administration of ACTH can control spasms in patients with adrenal suppression, suggesting that the effect is independent of adrenal glucocorticoid release.</p><p>Corticotropin may have direct anticonvulsant effects, perhaps via suppression of corticotropin-releasing hormone (CRH), an endogenous neuropeptide that may provoke convulsions in immature brain. This theory was suggested by a report in which administration of high-dose ACTH to rats resulted in a reduction of the expression of the <em>CRH</em> gene in the amygdala [<a href="#rid52">52,53</a>]. This reduction occurred in animals with and without adrenalectomy and thus was independent of endogenous cortisol production. The effect was reproduced by a peptide fragment of ACTH without corticotrophic activity and abolished by a melanocortin receptor antagonist.</p><p class="headingAnchor" id="H2206828919"><span class="h2">Vigabatrin</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">Vigabatrin</a> is an irreversible inhibitor of gamma-aminobutyric acid (GABA)-transaminase and thus raises the concentration of GABA in the central nervous system. Concerns regarding toxicity must be balanced against its efficacy.</p><p class="headingAnchor" id="H2712145213"><span class="h3">Dose and administration</span><span class="headingEndMark"> — </span>We use the dosing regimen for <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> recommended by the PERC, as found in the table  (<a class="graphic graphic_table graphicRef134829" href="/z/d/graphic/134829.html" rel="external">table 1</a>) [<a href="#rid18">18</a>]. A typical dosing escalation scale of vigabatrin in infantile spasms uses an initial dose of 50 mg/kg per day, escalating to 100 to 150 mg/kg per day as required for clinical response [<a href="#rid6">6</a>]. Efficacy is assessed at two weeks after dose change. The 2010 consensus report suggests that patients who respond to therapy can be continued on the drug for six months, with continued evaluation for toxicity and assessment of risks and benefits [<a href="#rid6">6</a>]. Vigabatrin should be withdrawn earlier in patients who do not respond to treatment.</p><p>However, while several variations have been studied, the optimal dose and duration of <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> therapy for infantile spasms is unclear [<a href="#rid6">6</a>]. In a review of nine prospective studies of vigabatrin in infantile spasms, doses from 18 to 200 mg/kg per day were used [<a href="#rid37">37</a>]. The evidence was insufficient to determine if response to vigabatrin was dose dependent. In a single-masked trial that compared low-dose (18 to 36 mg/kg per day) and high-dose (100 to 148 mg/kg per day) regimens, cessation of spasms for 7 consecutive days within the first 14 days of vigabatrin therapy was significantly greater in the high-dose group (36 versus 11 percent), and the time to response was shorter [<a href="#rid54">54</a>]. A randomized trial in 221 patients with newly diagnosed infantile spasms also suggested greater efficacy for high-dose vigabatrin [<a href="#rid55">55</a>]. Children were randomly assigned to either high-dose (100 to 148 mg/kg per day) or low-dose (18 to 36 mg/kg per day) vigabatrin for 14 to 21 days. More patients in the high-dose group became seizure free with normalization of a video-EEG (15.9 versus 7.0 percent). The benefit appeared to be maintained in a subsequent open-label treatment phase for up to three years. Adverse events were similar in both groups.</p><p>Among the studies reviewed in the 2004 American Academy of Neurology (AAN) practice parameter, the time from initiation of therapy to cessation of spasms ranged from 12 to 35 days [<a href="#rid37">37</a>]. In one prospective study of 19 children with infantile spasms, whose underlying cause was hypoxic-ischemic encephalopathy or not identified and who were treated for a mean of 5.1 months, withdrawal of <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> over a 30- to 60-day period was not associated with relapse within a mean follow-up time of 26 months [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H3419736795"><span class="h3">Adverse effects and monitoring</span><span class="headingEndMark"> — </span>Children treated with <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> can develop irreversible retinal dysfunction and concentric visual field constriction [<a href="#rid57">57,58</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual field constriction</strong> – The frequency of this complication in children has been difficult to estimate, in part because of the poor reliability of visual field testing in children younger than six to eight years of age and in those with cognitive impairment [<a href="#rid59">59</a>]. However, several studies have suggested that the risk of visual field constriction is relatively low in infants [<a href="#rid60">60,61</a>]. In a retrospective review of 284 children taking <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> undergoing a total of 1281 visual assessments over a 10-year period, only 2 out of 284 (0.7 percent) had evidence of ocular toxicity that was definitely attributable to vigabatrin, and four children (1.4 percent) had optic atrophy that was considered possibly attributable. This is in contrast to studies done in adults, in which the risk of mild to severe bilateral concentric visual field constriction related to vigabatrin is estimated to be 30 to 50 percent [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1">In one series, only 1 of 16 children with infantile spasms who were treated with <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> for a mean of 21 months had visual field abnormalities at age 6 to 12 years, suggesting that young age might be protective [<a href="#rid63">63</a>]. However, in another series that included 32 school-aged children with infantile spasms treated with vigabatrin in infancy, the prevalence of visual field defects was 34 percent, similar to that in adults [<a href="#rid64">64</a>]. The frequency of defects increased with treatment duration and cumulative dose, ranging from 9 percent in those treated for &lt;12 months to 63 percent in those treated for &gt;24 months. Another observational series using electroretinograms (ERG) in infants with infantile spasms treated with vigabatrin confirmed that treatment duration is a key factor in determining likelihood of retinal damage: ERG amplitude was reduced from baseline within 6, 12, and 30 months of treatment initiation in 5, 13, and 38 percent of patients, respectively [<a href="#rid65">65</a>]. The impact of these changes on function and quality of life has not been well documented. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Vigabatrin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Monitoring for vigabatrin-associated vision loss is challenging, as visual fields are difficult to assess in infancy. Ophthalmologic evaluation is recommended prior to initiation of therapy, every three to six months during therapy, and three to six months after treatment has been discontinued [<a href="#rid6">6</a>]. In the United States, prescribers, patients, and pharmacies must participate in the Risk Evaluation and Mitigation Strategies (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Frems%2Findex.cfm&amp;token=3Adm4xoOmtiUj4xfH9EHbssWX3lz3OgkCpb69dkuqlw2YfoJjWzr%2FgtQuYwkZq4ynX7SIdDEGaXejS%2F44xpZ1w%3D%3D&amp;TOPIC_ID=6186" target="_blank">REMS</a>) program.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI abnormalities</strong> – Vigabatrin-associated brain abnormalities on magnetic resonance imaging (VABAM) have been reported in infants treated for infantile spasms [<a href="#rid66">66-68</a>]. These abnormalities (hyperintense lesions on T2-weighted images with restricted diffusion on diffusion-weighted imaging in the basal ganglia, thalamus, brainstem, and dentate nucleus of the cerebellum) appear to be a subclinical, dose-related phenomenon that usually resolves with discontinuation of <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a>. However, there are rare reports of more fulminant, symptomatic VABAM [<a href="#rid69">69,70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Vigabatrin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor adverse effects</strong> – The incidence of minor adverse effects (eg, drowsiness, irritability, hypotonia, sleep disturbance, weight gain) with <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> is low and usually does not necessitate discontinuation of the drug. In the three randomized controlled trials of vigabatrin, sedation was noted in 9 to 24 percent, irritability in 4 to 9 percent, insomnia in 9 percent, and hypotonia in 9 percent [<a href="#rid37">37</a>]. Vigabatrin was discontinued in 0 to 6 percent of children in these trials because of adverse effects.</p><p></p><p class="headingAnchor" id="H3019950562"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">Vigabatrin</a> may be effective as initial treatment for infantile spasms, although most reviews have found superior short-term outcomes with hormonal therapy [<a href="#rid6">6,7,11,51,54,71</a>]. An exception is that vigabatrin is considered to be the most effective treatment for infantile spasms in patients with tuberous sclerosis complex [<a href="#rid11">11,51,72</a>]. (See  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Initial ASM therapy'</a>.)</p><p>In an earlier AAN practice parameter review, nine prospective studies of <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> were reviewed [<a href="#rid37">37</a>]. The time from onset of treatment to cessation of spasms ranged from 12 to 35 days. The time to EEG response ranged from 7 to 35 days, and 11 to 83 percent of children had resolution of hypsarhythmia. In the National Infantile Spasms Consortium prospective cohort study, freedom from treatment failure was higher with corticotropin and oral glucocorticoid therapy (46 percent and 44 percent respectively) compared with vigabatrin (37 percent); in the vigabatrin group, freedom from treatment failure was higher among infants with tuberous sclerosis complex (13 of 21, 62 percent) compared with other infants (19 of 65, 29 percent) [<a href="#rid51">51</a>].</p><p>One of the largest reports of <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> as initial monotherapy comes from an uncontrolled retrospective study of 250 infants with infantile spasms in which vigabatrin was given as monotherapy [<a href="#rid73">73</a>]. Initial suppression of spasms was noted in 68 percent. A placebo-controlled trial of vigabatrin for infantile spasms randomly assigned 40 infants to receive vigabatrin or placebo for five days, followed by open treatment with vigabatrin for at least 24 weeks [<a href="#rid74">74</a>]. By the end of the five-day double-blind phase, spasm cessation had occurred more frequently in children treated with vigabatrin compared with placebo (35 versus 10 percent), but this result did not achieve statistical significance. At the end of open treatment, spasms had resolved in 42 percent of patients. In prospective randomized controlled trials of vigabatrin, treatment response for children with infantile spasms of known etiology ranged from 21 to 44 percent, and response for infantile spasms of unknown etiology from 27 to 57 percent [<a href="#rid9">9,54,74,75</a>]. The infantile spasms relapse rate ranged from 8 to 20 percent in those trials in which relapses were assessed [<a href="#rid54">54,74,75</a>].</p><p class="headingAnchor" id="H4036758018"><span class="h2">Pyridoxine</span><span class="headingEndMark"> — </span>Some infants with West syndrome have been reported to respond to treatment with high-dose <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a> (vitamin B6, 30 to 400 mg daily) or pyridoxal 5'-phosphate. Although vitamin B6 deficiency or dependency is a rare cause of the disorder, it is important not to miss it because of the remarkable response to treatment. (See  <a class="medical medical_review" href="/z/d/html/6163.html" rel="external">"Infantile epileptic spasms syndrome: Etiology and pathogenesis", section on 'Inborn errors of metabolism'</a>.)</p><p>Outside of pyridoxine-dependent epilepsy, high-quality data for <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a> in treatment of infantile spasms are lacking [<a href="#rid5">5</a>]. The response rates to pyridoxine ranged from 13 to 29 percent in two uncontrolled, prospective, open-label studies [<a href="#rid76">76,77</a>].</p><p class="headingAnchor" id="H4278884139"><span class="h1">MONITORING TREATMENT RESPONSE</span><span class="headingEndMark"> — </span>An expert consensus panel has defined effective treatment of infantile epileptic spasms syndrome (IESS) as complete cessation of spasms and resolution of hypsarhythmia on EEG [<a href="#rid6">6</a>]. However, hypsarhythmia is present in only 60 percent of children with epileptic spasms [<a href="#rid78">78</a>], and there is poor interrater reliability to diagnose hypsarhythmia on EEG [<a href="#rid79">79</a>]. Hence, resolution of spasms is the main treatment outcome to target in this vulnerable group of patients. Per the West Delphi group consensus statement, this outcome is measured as the absence of witnessed spasms beginning within 14 days of commencement of treatment, and for ≥28 consecutive days from the last witnessed spasm [<a href="#rid2">2</a>].</p><p>Parents, caregivers, and trained observers may miss the occurrence of spasms, especially if they are subtle. Less commonly, they may "overcount" imitators of spasms [<a href="#rid80">80</a>]. As a result, overnight inpatient video-EEG monitoring is ideally used to assess treatment response in children with infantile spasms. We do overnight inpatient video-EEG monitoring at two weeks from the start of therapy and as clinically indicated thereafter. However, resource limitations may preclude inpatient monitoring in many institutions. While there is no consensus on a standard duration of the post-treatment EEG needed for assessing treatment response, one study found that outpatient EEG (with median duration of 150 minutes, range 90 to 240 minutes), but not routine EEG, provided up to 85 percent sensitivity for detection of treatment failure [<a href="#rid81">81</a>]. Therefore, outpatient EEG monitoring may be used as an alternative to overnight inpatient monitoring for follow-up at two weeks of treatment. (See  <a class="medical medical_review" href="/z/d/html/6145.html" rel="external">"Infantile epileptic spasms syndrome: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H90444387"><span class="h1">DURATION OF INITIAL THERAPY</span><span class="headingEndMark"> — </span>In general, a successful treatment response for infantile epileptic spasms syndrome (IESS) is defined by resolution of epileptic spasms and hypsarhythmia within two weeks of treatment initiation [<a href="#rid47">47</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal therapy</strong> – We begin a taper of hormonal therapy after two weeks of therapy at the maximum dose, in general agreement with the 2010 consensus statement [<a href="#rid6">6</a>] and the Pediatric Epilepsy Research Consortium (PERC) treatment guidelines  (<a class="graphic graphic_table graphicRef134829" href="/z/d/graphic/134829.html" rel="external">table 1</a>) [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">The effect of adrenocorticotropic hormone (ACTH) persists when therapy is discontinued. However, the optimal duration of treatment is uncertain. Although some series suggest that hormonal therapy should be continued for many months [<a href="#rid82">82,83</a>], prolonged therapy may not be necessary and may be hazardous. As an example, in a comparison trial of low-dose ACTH and <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> in 24 patients, response occurred within two weeks of initiation of therapy in 75 percent of patients who responded [<a href="#rid29">29</a>]. Five patients who responded relapsed within 12 to 33 months with clinical seizures but not hypsarhythmia; four of these responded to a second course of treatment. Many side effects of hormonal therapy are associated with long-term use. (See <a class="local">'Adverse effects of hormonal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vigabatrin</strong> – We agree with the 2010 consensus report suggestion that patients who respond to <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> therapy can be continued on vigabatrin for six months, with ongoing evaluation for toxicity and assessment of risks and benefits [<a href="#rid6">6</a>]. Some protocols wean vigabatrin over one month after a three-month trial [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">Vigabatrin</a> should be withdrawn earlier in patients who do not respond to treatment.</p><p></p><p class="headingAnchor" id="H1842045002"><span class="h1">RELAPSES</span><span class="headingEndMark"> — </span>Relapses of infantile spasms in patients with infantile epileptic spasms syndrome (IESS) are not uncommon among patients who responded to an initial treatment course. No data are available to guide therapy in these cases. Often, a second course of the agent that was previously effective in obtaining control is administered [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H90280898"><span class="h1">TREATMENT FAILURE</span><span class="headingEndMark"> — </span>Alternative treatments may be considered for children who fail initial therapy with hormonal therapy and <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> and are therefore considered to have refractory spasms.</p><p class="headingAnchor" id="H3935923327"><span class="h2">Sequential therapy</span><span class="headingEndMark"> — </span>Lack of a successful response within two weeks should prompt a change in treatment strategy [<a href="#rid47">47</a>]. Our general approach after failure of the first standard treatment (hormonal or <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a>) is to switch to the alternative standard treatment (ie, "sequential therapy"). If the alternative standard treatment is unsuccessful, other options (eg, combination therapy, ketogenic diet, surgery) are considered on a case-by-case basis, but there is no consensus approach, and good-quality data are lacking.</p><p class="headingAnchor" id="H2288689248"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>Initial treatment with both hormonal therapy and <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> may be more effective than hormonal therapy alone, but more studies on toxicity and long-term effects are needed before this strategy should be adopted routinely.</p><p>In a multicenter open-label trial, 377 children with infantile spasms were randomly assigned to receive either hormonal therapy (<a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> minimum dose 10 mg orally four times per day or cosyntropin [tetracosactide depot] 0.5 mg intramuscular [IM] 40 international units every other day) <strong>plus</strong> <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> (100 mg/kg per day) or hormonal therapy alone [<a href="#rid84">84</a>]. By six weeks, the addition of vigabatrin resulted in a greater clinical seizure remission rate, defined as no seizures witnessed by parents or caregivers from day 14 through 42 (72 versus 57 percent; difference 15 percent, 95% CI 5.1-24.9). Adverse effects were similar in both groups, including rates of serious adverse reactions requiring hospitalization (9.1 versus 8.4 percent). Limitations of the trial included the large discrepancy between screened versus enrolled patients (766 versus 377), lack of objective measures of response and efficacy, and lack of long-term efficacy and safety endpoints. Additional studies are needed to determine whether these early results are sustained and not outweighed by increased toxicity and burdens of monitoring [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H1394779680"><span class="h2">Ketogenic diet</span><span class="headingEndMark"> — </span>A ketogenic diet may control spasms in cases refractory to first-line treatment, and it is the recommended treatment for infants with infantile spasms and pyruvate dehydrogenase deficiency. (See  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.)</p><p>A randomized controlled trial published in 2021 evaluated 91 children with epileptic spasms refractory to hormonal therapy and randomly assigned 46 to adjunctive treatment with the modified Atkins diet (a less restrictive form of the ketogenic diet) and 45 to the control group; all patients remained on their usual antiseizure medications [<a href="#rid86">86</a>]. At four weeks, treatment with the modified Atkins diet compared with control led to a higher rate of spasm cessation (24 versus 0 percent) and an increased proportion of children with &gt;50 percent reduction in spasms (65 versus 0 percent). Results from a small, underpowered randomized controlled trial published in 2019 suggested that the ketogenic diet has similar short-term efficacy compared with adrenocorticotropin hormone (ACTH), mainly for infants with prior <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> treatment [<a href="#rid87">87</a>].</p><p>A 2018 systematic review identified 13 observational studies (341 patients) and no randomized trials evaluating the ketogenic diet for infantile spasms [<a href="#rid88">88</a>]. Across studies, the median response rate (proportion achieving &gt;50 percent reduction in spasms within six months) was 65 percent. The median spasm-free rate was 35 percent within six months of diet initiation and 10 percent at 12 to 24 months. Infantile spasms of unknown etiology were associated with increased likelihood of response to the ketogenic diet. Adverse effects and developmental outcomes were not presented.</p><p class="headingAnchor" id="H3045159173"><span class="h2">Surgical treatment</span><span class="headingEndMark"> — </span>Although many patients with infantile spasms have diffuse abnormalities, some have a focal-cortical structural or metabolic abnormality that may respond to surgical excision [<a href="#rid89">89-92</a>].</p><p>Resective surgical treatment is considered in such patients when infantile spasms are refractory to medical treatment (approximately 30 to 40 percent of patients) and when there is no evidence of diffuse brain damage or degenerative or metabolic disease [<a href="#rid6">6</a>]. Surgery is not considered if the cortical resection would create an unacceptable new neurologic deficit. (See  <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">"Seizures and epilepsy in children: Refractory seizures", section on 'Epilepsy surgery'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Other antiseizure medications</span><span class="headingEndMark"> — </span>Other antiseizure medications are generally not as effective as first-line treatment of infantile spasms [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Valproate</strong> – Reports of treatment with <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproic acid</a> have inconsistent results [<a href="#rid37">37,93-96</a>]. Valproic acid may benefit 40 to 70 percent of patients who do not respond to ACTH [<a href="#rid93">93-96</a>]. However, the apparent response may reflect the natural history of infantile spasms rather than the effect of treatment [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1">High-quality data in the form of controlled trials of <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproate</a> for infantile spasms are lacking [<a href="#rid5">5,37</a>]. In one prospective open-label study, cessation of spasms and resolution of hypsarhythmia occurred in 73 and 91 percent of 22 children at six months from onset of treatment [<a href="#rid98">98</a>]. A majority responded in two weeks, but 23 percent relapsed, and thrombocytopenia developed in one-third. In the other open-label study, cessation of spasms occurred in 72 percent of children at three months from onset of treatment [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zonisamide</strong> – <a class="drug drug_pediatric" data-topicid="12612" href="/z/d/drug information/12612.html" rel="external">Zonisamide</a> is a sulfonamide derivative. Its primary mechanism of action appears to be related to blockage of voltage-dependent sodium and T-type calcium channels. In case series, zonisamide was associated with improvement in a minority of patients with infantile spasms, some of whom had failed to respond to <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a> or <a class="drug drug_pediatric" data-topicid="12873" href="/z/d/drug information/12873.html" rel="external">valproate</a> [<a href="#rid100">100-104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topiramate</strong> – Limited data on the efficacy of <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a> for infantile spasms have been mixed. Encouraging results were reported in an open-label study in 11 patients with refractory infantile spasms [<a href="#rid105">105,106</a>]. However, in a single-center retrospective study that included 31 patients with refractory infantile spasms treated with topiramate, only three patients achieved a nonsustained clinical remission [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sulthiame</strong> – Sulthiame, a sulfonamide derivative, is an antiseizure medication that is available in some countries outside the United States. A randomized, placebo-controlled trial of 37 infants between 3.5 and 15 months of age with newly diagnosed West syndrome (infantile spasms plus hypsarhythmia on EEG) found that infants randomly assigned to receive sulthiame plus <a class="drug drug_pediatric" data-topicid="12753" href="/z/d/drug information/12753.html" rel="external">pyridoxine</a> had a higher rate of complete response than those assigned to placebo plus pyridoxine (30 versus 0 percent) [<a href="#rid108">108</a>]. Follow-up in this study was short (only nine days); the long-term efficacy of sulthiame treatment is unknown.</p><p></p><p class="headingAnchor" id="H30"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H314691951"><span class="h2">Overall prognosis</span><span class="headingEndMark"> — </span>The overall prognosis is guarded for children with infantile epileptic spasms syndrome (IESS)  (<a class="graphic graphic_table graphicRef78369" href="/z/d/graphic/78369.html" rel="external">table 2</a>) [<a href="#rid109">109,110</a>]. The mortality rate varies from 3 to 33 percent [<a href="#rid109">109,111-113</a>], with the most important risk factor being significant respiratory system comorbidity. The higher mortality rates may be attributed in some part to a period effect and are likely lower overall in the setting of modern medical care. Other adverse outcomes include epilepsy, which may be intractable, and moderate to severe neurodevelopmental disability. However, approximately 25 percent of children with infantile spasms have a favorable long-term outcome with seizure freedom and good cognitive outcomes [<a href="#rid10">10,114,115</a>].</p><p class="headingAnchor" id="H4103820786"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>In a 2020 review, the underlying etiology of infantile spasms was considered the most important predictor of subsequent seizure and neurodevelopmental outcomes [<a href="#rid110">110</a>]. In studies with long-term follow-up (up to 50 years), a favorable cognitive outcome was observed in approximately 25 percent, while complete seizure freedom was achieved in approximately 33 percent. Favorable prognostic factors included early spasm recognition and treatment, short duration of hypsarhythmia, early treatment of spasm relapses or multifocal epileptic discharges on EEG, and prompt management of adverse effects.</p><p class="headingAnchor" id="H31"><span class="h2">Seizures and epilepsy</span></p><p class="headingAnchor" id="H955447647"><span class="h3">Infantile spasms and hypsarhythmia</span><span class="headingEndMark"> — </span>In natural history data from historical cohorts before effective treatments were available, clinical spasms stopped by three years of age in approximately one-half of children with infantile spasms and rarely persist after five years of age [<a href="#rid116">116-119</a>]. Hypsarhythmia also tends to resolve with maturation [<a href="#rid97">97,116</a>]. (See  <a class="medical medical_review" href="/z/d/html/6145.html" rel="external">"Infantile epileptic spasms syndrome: Clinical features and diagnosis", section on 'Clinical course'</a>.)</p><p class="headingAnchor" id="H2582323300"><span class="h3">Other seizure types</span><span class="headingEndMark"> — </span>Fifty to 90 percent of patients with infantile spasms develop other seizure types [<a href="#rid6">6,109,111,119,120</a>]. In general, patients with infantile spasms of known etiology are more likely to develop other seizure types than those with infantile spasms of unknown etiology (formerly termed cryptogenic or idiopathic; 58 versus 35 percent) [<a href="#rid121">121,122</a>]. In one report, seizure outcomes were more favorable for patients with infantile spasms of unknown etiology as opposed to known etiology, and for those with earlier onset of spasms (&lt;4 months versus 4 to 8 months versus 8 months) [<a href="#rid15">15</a>], although these relationships have not been found in other studies [<a href="#rid123">123</a>]. In cases with identified causes, seizure outcome is better in some etiologies than in others. As examples, outcome for seizure control is relatively good in patients with infantile spasms and neurofibromatosis type 1 [<a href="#rid124">124</a>] or Down syndrome [<a href="#rid125">125-127</a>].</p><p class="headingAnchor" id="H32"><span class="h3">Lennox-Gastaut syndrome</span><span class="headingEndMark"> — </span>Some patients with infantile spasms develop a severe form of epilepsy known as Lennox-Gastaut syndrome  (<a class="graphic graphic_table graphicRef78369" href="/z/d/graphic/78369.html" rel="external">table 2</a>) [<a href="#rid6">6,128,129</a>]. This syndrome includes characteristic types of seizures (typical drop attacks and axial tonic seizures) and specific EEG patterns [<a href="#rid130">130</a>]. Children with infantile spasms of unknown etiology are less likely to develop Lennox-Gastaut syndrome compared with children who have a known etiology [<a href="#rid129">129</a>]. (See  <a class="medical medical_review" href="/z/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>.)</p><p class="headingAnchor" id="H33"><span class="h2">Developmental outcome</span><span class="headingEndMark"> — </span>Developmental impairment occurs in 75 to 85 percent of patients with infantile spasms [<a href="#rid131">131,132</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of underlying disease</strong> – The long-term prognosis for developmental outcome in infantile spasms appears to depend upon the underlying disease [<a href="#rid121">121,122,133-135</a>]. In general, outcome is better for patients with infantile spasms of unknown etiology than for those with infantile spasms of known etiology [<a href="#rid78">78,111,122,123,135,136</a>]. Some infants with infantile spasms of unknown etiology do remarkably well, particularly if detected early and treated effectively. In one study of 57 infants with infantile spasms who were followed for 12 to 60 months, severe cognitive impairment (developmental score &lt;50) occurred in 44 percent; 28 percent had mild impairment (developmental score &lt;70) or no impairment [<a href="#rid122">122</a>]. The mean developmental score was higher in the unknown-cause cohort compared with the group with identified cause (71.2 versus 48.4). Neurologic deficits, including motor impairment (eg, hypertonia, spasticity, and hemiparesis) and visual and/or hearing abnormalities occurred less often in the group with no known etiology (24 versus 75 percent). Another study of 95 children with infantile spasms found that the adjusted odds ratio for the later development of autism spectrum disorder was higher in the known etiology group versus the unknown etiology group (8.73 versus 1.55) [<a href="#rid135">135</a>]. In a case series of 68 children, developmental delay was noted in 100 percent of patients with infantile spasms of known etiology [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1">Cognitive deficits are also common among children with infantile spasms of unknown etiology, whose spasms cease soon after onset and do not recur. In one report, neurodevelopment was assessed at four to six years of age in 15 children whose spasms resolved before one year of age [<a href="#rid137">137</a>]. Intelligence was normal in 12 children. However, 5 of the 12 had specific cognitive deficits, including problems with attention, language, memory, and visual motor skills. In a later retrospective cohort study of 133 children with infantile spasms of unknown cause and at least six months of follow-up, developmental delay was documented in 85 percent [<a href="#rid138">138</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effect of treatment</strong> – It is possible but unproven that treatment of infantile spasms improves developmental and other long-term outcomes; many observational but no randomized studies have reported that treated patients were more likely to have normal intelligence at follow-up than untreated patients [<a href="#rid5">5,83,123,139,140</a>].</p><p></p><p class="bulletIndent1">Proposed mechanisms underlying improved outcome with hormonal therapy include acceleration of the physiologic rate of maturation [<a href="#rid83">83</a>] or deactivation of a neuroendocrine stress response. The pretreatment neurologic status may also be important; in one study, normal cognitive outcome was found in all 25 patients who had no or only mild mental deterioration at presentation but in only 3 of 12 patients who had marked or severe deterioration before treatment [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1">Limited data suggest developmental outcomes may be better with treatment with adrenocorticotropin hormone (ACTH) rather than <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> [<a href="#rid5">5,7</a>]. In a randomized trial of 107 patients with infantile spasms that compared vigabatrin with hormonal treatment, cognitive outcomes at 12 to 14 months were better in those who had no identified underlying cause and had received hormonal treatment [<a href="#rid26">26</a>]. When reassessed at a mean age of four years, developmental and epilepsy outcomes were similar between the two treatment groups; however, for those 77 patients with no identified etiology ("cryptogenic") of infantile spasms, cognitive outcomes remained better in those assigned to hormonal treatment [<a href="#rid142">142</a>].</p><p></p><p class="bulletIndent1">Outcome may also be better if therapy is started soon after presentation [<a href="#rid5">5</a>]. Among cases with no known etiology of spasms, normal outcome occurred in more patients treated within one to two months of the onset of seizures compared with those treated after one or two months (70 to 85 versus 20 to 25 percent) [<a href="#rid82">82,83,133,141,143</a>]. However, in one prospective study that used a defined treatment regimen for ACTH or <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> and 24-hour video-EEG monitoring to determine response, the prognosis was poor for long-term outcome independent of response to therapy (cessation of spasms and resolution of hypsarhythmia), treatment agent used (ACTH or prednisone), or delay between presentation and treatment [<a href="#rid111">111</a>]. By contrast, in the clinical trial comparing hormonal treatment with <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a>, an analysis of the effect of lead time to treatment on outcome found that each increase in category of lead-time duration (within 7 days, 8 to 14 days, 15 days to 1 month, 1 to 2 months, greater than 2 months) was associated with worse developmental outcome at four years [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">In some reports, prolonged treatment (10 or more months) with high-dose corticotropin (80 units every two days) appeared to improve the prognosis for mental and motor development [<a href="#rid82">82,83,140</a>]. However, in a long-term follow-up study of 214 children, prognosis was not improved by larger (120 to 160 units) compared with smaller doses (20 to 40 units) of ACTH, although fewer side effects occurred in the latter [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1">Studies assessing the benefit of therapy on long-term outcomes are both conflicting and difficult to evaluate; most of the available studies are retrospective and lack specific treatment courses or objective criteria for response. Because of these limitations, the American Academy of Neurology (AAN) systematic review of treatment for infantile spasms concluded that successful treatment of infantile spasms possibly improves the long-term prognosis [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H35"><span class="h2">Outcome in adults</span><span class="headingEndMark"> — </span>Little information is available on very-long-term outcomes of children with infantile spasms. Some adults with a history of infantile spasms have normal intelligence and socioeconomic status, as illustrated by one report of 214 children born between 1960 and 1976 who were followed for 20 to 35 years or until death [<a href="#rid114">114</a>]. Death occurred in 31 percent at 3 months to 30 years of age. Intelligence was normal or mildly impaired in 24 percent of the survivors, and 33 percent had no seizures. Some patients with normal intelligence and socioeconomic status had infantile spasms with identified etiology or focal EEG findings. All patients with a good outcome had short delays between presentation and treatment and responded to ACTH therapy.</p><p class="headingAnchor" id="H2504927989"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">"Society guideline links: Seizures and epilepsy in children"</a>.)</p><p class="headingAnchor" id="H36"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choosing initial therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormonal therapy for</strong> <strong>most infants</strong> – For most children with infantile epileptic spasms syndrome (IESS), we suggest initial treatment with hormonal therapy using <a class="drug drug_pediatric" data-topicid="13181" href="/z/d/drug information/13181.html" rel="external">corticotropin injection gel</a> (adrenocorticotropin hormone [ACTH]) or oral glucocorticoids rather than <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This recommendation is based upon advantages of hormonal therapy in effectiveness, risk profile, and longer experience compared with vigabatrin. (See <a class="local">'Choosing initial therapy'</a> above and <a class="local">'Hormonal therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vigabatrin</strong><strong> for</strong> <strong>infants with tuberous sclerosis complex</strong> – For infants with IESS and tuberous sclerosis complex, <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> is first-line therapy. (See <a class="local">'Choosing initial therapy'</a> above and <a class="local">'Vigabatrin'</a> above and  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Initial ASM therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing</strong> – Typical dose and taper recommendations for hormonal therapy and <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> are listed in the table  (<a class="graphic graphic_table graphicRef134829" href="/z/d/graphic/134829.html" rel="external">table 1</a>). (See <a class="local">'Corticotropin (ACTH)'</a> above and <a class="local">'Glucocorticoids'</a> above and <a class="local">'Vigabatrin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hormonal therapy</strong> – Adverse effects are common and include hypertension, irritability, infection, reversible cerebral atrophy, and rarely death due to sepsis. Monitoring should include measurement of blood pressure (baseline and once weekly) and serum glucose, potassium, and sodium levels (baseline and every other week). Infectious contacts should be avoided, and infections should be treated promptly. (See <a class="local">'Adverse effects of hormonal therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Vigabatrin</strong> – Permanent visual field constriction due to retinal toxicity is a potentially severe adverse effect of <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a>. Ophthalmologic evaluation and monitoring is recommended. (See <a class="local">'Adverse effects and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring treatment response</strong> – Use of overnight inpatient video-EEG to evaluate treatment response is ideal; however, outpatient EEG studies up to 240 minutes can be considered as an alternative. Clinical observation frequently misses subtle spasms, and shorter EEGs are less sensitive for detecting hypsarhythmia. (See <a class="local">'Monitoring treatment response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of initial therapy</strong> – Hormonal therapy is generally given at the maximum dose for 14 days, followed by a gradual taper starting on day 15, as outlined in the table  (<a class="graphic graphic_table graphicRef134829" href="/z/d/graphic/134829.html" rel="external">table 1</a>). <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">Vigabatrin</a> is generally continued for six months in patients who respond to therapy, with continued evaluation for toxicity. (See <a class="local">'Duration of initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapses</strong> – For infants who relapse after termination of initial therapy, a second course of the agent that was effective in obtaining control should be administered. (See <a class="local">'Relapses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory infantile spasms</strong> – Lack of a successful response to initial therapy within two weeks should prompt a change in treatment strategy. Alternatives for children who do not respond to hormonal therapy or <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sequential therapy</strong> – Our general approach after failure of the first standard treatment (hormonal or <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a>) is to switch to the alternative standard treatment. (See <a class="local">'Sequential therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combination therapy</strong> – Treatment with both hormonal therapy and <a class="drug drug_pediatric" data-topicid="13101" href="/z/d/drug information/13101.html" rel="external">vigabatrin</a> may be more effective than hormonal therapy alone, and many centers and protocols utilize combination therapy as first-line management. (See <a class="local">'Combination therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ketogenic diet</strong> – A ketogenic diet may control spasms in cases refractory to first-line treatment. (See <a class="local">'Ketogenic diet'</a> above and  <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">"Ketogenic dietary therapies for the treatment of epilepsy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery</strong> – Patients with refractory infantile spasms who have focal brain lesions and no evidence of diffuse brain damage or degenerative or metabolic disease should be evaluated for early epilepsy surgical intervention. (See <a class="local">'Surgical treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – The overall prognosis for children with IESS is guarded. Mortality ranges from 3 to 33 percent, and most patients will have impaired neurodevelopmental outcome and/or epilepsy  (<a class="graphic graphic_table graphicRef78369" href="/z/d/graphic/78369.html" rel="external">table 2</a>). There is insufficient evidence to conclude that successful treatment of infantile spasms improves the long-term prognosis, although that is suggested by some observational data. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="headingAnchor" id="H3148841486"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledges Daniel G Glaze, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022; 63:1349.</a></li><li><a class="nounderline abstract_t">Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004; 45:1416.</a></li><li class="breakAll">Infantile spasms syndrome. In: Epilepsies in children, young people and adults. National Institute for Health and Care Excellence (NICE) guideline [NG217]. https://www.nice.org.uk/guidance/ng217/chapter/6-Treating-childhood-onset-epilepsies#infantile-spasms-syndrome (Accessed on August 08, 2023).</li><li><a class="nounderline abstract_t">O'Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011; 52:1359.</a></li><li><a class="nounderline abstract_t">Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78:1974.</a></li><li><a class="nounderline abstract_t">Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010; 51:2175.</a></li><li><a class="nounderline abstract_t">Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia 2015; 56:1185.</a></li><li><a class="nounderline abstract_t">Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. Epilepsy Behav 2009; 14:674.</a></li><li><a class="nounderline abstract_t">Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364:1773.</a></li><li><a class="nounderline abstract_t">Hussain SA, Shinnar S, Kwong G, et al. Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone. Epilepsia 2014; 55:103.</a></li><li><a class="nounderline abstract_t">Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2013; :CD001770.</a></li><li><a class="nounderline abstract_t">Rosati A, Ilvento L, Lucenteforte E, et al. Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. Epilepsia 2018; 59:297.</a></li><li><a class="nounderline abstract_t">Sánchez Fernández I, Amengual-Gual M, Barcia Aguilar C, et al. Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome. Epilepsia 2023; 64:630.</a></li><li class="breakAll">Depot (cosyntropin injection 1 mg/mL) Canada product monograph revision November 2, 2012. Health Canada Drug Product Database. Available at: http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp.</li><li><a class="nounderline abstract_t">Hamano S, Yamashita S, Tanaka M, et al. Therapeutic efficacy and adverse effects of adrenocorticotropic hormone therapy in west syndrome: differences in dosage of adrenocorticotropic hormone, onset of age, and cause. J Pediatr 2006; 148:485.</a></li><li><a class="nounderline abstract_t">Oguni H, Yanagaki S, Hayashi K, et al. Extremely low-dose ACTH step-up protocol for West syndrome: maximum therapeutic effect with minimal side effects. Brain Dev 2006; 28:8.</a></li><li><a class="nounderline abstract_t">Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996; 97:375.</a></li><li><a class="nounderline abstract_t">Knupp KG, Coryell J, Nickels KC, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol 2016; 79:475.</a></li><li><a class="nounderline abstract_t">Baram TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West syndrome? Brain Dev 2001; 23:647.</a></li><li><a class="nounderline abstract_t">Hodgeman RM, Kapur K, Paris A, et al. Effectiveness of once-daily high-dose ACTH for infantile spasms. Epilepsy Behav 2016; 59:4.</a></li><li><a class="nounderline abstract_t">Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr 1994; 124:803.</a></li><li><a class="nounderline abstract_t">Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev 1999; 21:461.</a></li><li><a class="nounderline abstract_t">Ito M, Aiba H, Hashimoto K, et al. Low-dose ACTH therapy for West syndrome: initial effects and long-term outcome. Neurology 2002; 58:110.</a></li><li><a class="nounderline abstract_t">Heiskala H, Riikonen R, Santavuori P, et al. West syndrome: individualized ACTH therapy. Brain Dev 1996; 18:456.</a></li><li><a class="nounderline abstract_t">Snead OC 3rd. West syndrome: individualized ACTH therapy, by Heiskala et al. Brain Dev 1996; 18:466.</a></li><li><a class="nounderline abstract_t">Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4:712.</a></li><li><a class="nounderline abstract_t">Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983; 24:135.</a></li><li><a class="nounderline abstract_t">Riikonen R, Donner M. ACTH therapy in infantile spasms: side effects. Arch Dis Child 1980; 55:664.</a></li><li><a class="nounderline abstract_t">Hrachovy RA, Frost JD Jr, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr 1983; 103:641.</a></li><li><a class="nounderline abstract_t">Perheentupa J, Riikonen R, Dunkel L, Simell O. Adrenocortical hyporesponsiveness after treatment with ACTH of infantile spasms. Arch Dis Child 1986; 61:750.</a></li><li><a class="nounderline abstract_t">Bobele GB, Ward KE, Bodensteiner JB. Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study. Am J Dis Child 1993; 147:223.</a></li><li><a class="nounderline abstract_t">Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms. J Child Neurol 2007; 22:1360.</a></li><li><a class="nounderline abstract_t">McGarry L, Messer R, Cree-Green M, et al. Incidence of Hypertension Among Children Treated With Adrenocorticotropic Hormone (ACTH) or Prednisolone for Infantile Spasms. J Child Neurol 2020; 35:215.</a></li><li><a class="nounderline abstract_t">Doré-Brabant G, Laflamme G, Millette M, et al. Adrenal insufficiency among children treated with hormonal therapy for infantile spasms. Epilepsia 2022; 63:2350.</a></li><li class="breakAll">Acthar Gel (repository corticotropin injection) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/008372s071lbl.pdf (Accessed on December 21, 2021).</li><li><a class="nounderline abstract_t">Kusse MC, van Nieuwenhuizen O, van Huffelen AC, et al. The effect of non-depot ACTH(1-24) on infantile spasms. Dev Med Child Neurol 1993; 35:1067.</a></li><li><a class="nounderline abstract_t">Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004; 62:1668.</a></li><li><a class="nounderline abstract_t">Hrachovy RA, Frost JD Jr, Kellaway P. Sleep characteristics in infantile spasms. Neurology 1981; 31:688.</a></li><li><a class="nounderline abstract_t">Lagenstein I, Willig RP, Kühne D. Cranial computed tomography (CCT) findings in children treated with ACTH and dexamethasone: first results. Neuropadiatrie 1979; 10:370.</a></li><li><a class="nounderline abstract_t">Maekawa K, Ohta H, Tamai I. Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases. Neuropadiatrie 1980; 11:80.</a></li><li><a class="nounderline abstract_t">Hara K, Watanabe K, Miyazaki S, et al. Apparent brain atrophy and subdural hematoma following ACTH therapy. Brain Dev 1981; 3:45.</a></li><li><a class="nounderline abstract_t">Carollo C, Marin G, Scanarini M, et al. CT and ACTH treatment in infantile spasms. Childs Brain 1982; 9:347.</a></li><li><a class="nounderline abstract_t">Ito M, Miyajima T, Fujii T, Okuno T. Subdural hematoma during low-dose ACTH therapy in patients with west syndrome. Neurology 2000; 54:2346.</a></li><li><a class="nounderline abstract_t">Baier WK. Interference of cortisone and ACTH with brain development? A survey of experimental studies in mice and rats. Neuropadiatrie 1980; 11:186.</a></li><li><a class="nounderline abstract_t">Weichsel ME Jr. The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurological hazards. Ann Neurol 1977; 2:364.</a></li><li><a class="nounderline abstract_t">Eidlitz-Markus T, Kivity S, Goldberg-Stern H, et al. Effect of high-dose glucocorticosteroid treatment for infantile spasms on quantitative bone parameters later in life. J Child Neurol 2012; 27:74.</a></li><li><a class="nounderline abstract_t">Hussain SA. Treatment of infantile spasms. Epilepsia Open 2018; 3:143.</a></li><li><a class="nounderline abstract_t">Chang YH, Chen C, Chen SH, et al. Effectiveness of corticosteroids versus adrenocorticotropic hormone for infantile spasms: a systematic review and meta-analysis. Ann Clin Transl Neurol 2019; 6:2270.</a></li><li><a class="nounderline abstract_t">Li S, Zhong X, Hong S, et al. Prednisolone/prednisone as adrenocorticotropic hormone alternative for infantile spasms: a meta-analysis of randomized controlled trials. Dev Med Child Neurol 2020; 62:575.</a></li><li><a class="nounderline abstract_t">Guang S, Mao L, Zhong L, et al. Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis. Front Neurol 2022; 13:772333.</a></li><li><a class="nounderline abstract_t">Grinspan ZM, Knupp KG, Patel AD, et al. Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort. Neurology 2021; 97:e1217.</a></li><li><a class="nounderline abstract_t">Brunson KL, Khan N, Eghbal-Ahmadi M, Baram TZ. Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression. Ann Neurol 2001; 49:304.</a></li><li><a class="nounderline abstract_t">Snead OC 3rd. How does ACTH work against infantile spasms? Bedside to bench. Ann Neurol 2001; 49:288.</a></li><li><a class="nounderline abstract_t">Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57:1416.</a></li><li><a class="nounderline abstract_t">Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol 2010; 25:1340.</a></li><li><a class="nounderline abstract_t">Capovilla G, Beccaria F, Montagnini A, et al. Short-term nonhormonal and nonsteroid treatment in West syndrome. Epilepsia 2003; 44:1085.</a></li><li><a class="nounderline abstract_t">Koul R, Chacko A, Ganesh A, et al. Vigabatrin associated retinal dysfunction in children with epilepsy. Arch Dis Child 2001; 85:469.</a></li><li><a class="nounderline abstract_t">Iannetti P, Spalice A, Perla FM, et al. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 2000; 106:838.</a></li><li><a class="nounderline abstract_t">Nabbout R. A risk-benefit assessment of treatments for infantile spasms. Drug Saf 2001; 24:813.</a></li><li><a class="nounderline abstract_t">Jonsson H, Lehto M, Vanhatalo S, et al. Visual field defects after vigabatrin treatment during infancy: retrospective population-based study. Dev Med Child Neurol 2022; 64:641.</a></li><li><a class="nounderline abstract_t">Schein Y, Miller KD, Han Y, et al. Ocular examinations, findings, and toxicity in children taking vigabatrin. J AAPOS 2022; 26:187.e1.</a></li><li><a class="nounderline abstract_t">Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010; 51:2423.</a></li><li><a class="nounderline abstract_t">Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50:206.</a></li><li><a class="nounderline abstract_t">Riikonen R, Rener-Primec Z, Carmant L, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol 2015; 57:60.</a></li><li><a class="nounderline abstract_t">Westall CA, Wright T, Cortese F, et al. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Neurology 2014; 83:2262.</a></li><li><a class="nounderline abstract_t">Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009; 50:184.</a></li><li><a class="nounderline abstract_t">Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50:195.</a></li><li><a class="nounderline abstract_t">Reyes Valenzuela G, Crespo A, Princich J, et al. Vigabatrin-associated brain abnormalities on MRI and other neurological symptoms in patients with West syndrome. Epilepsy Behav 2022; 129:108606.</a></li><li><a class="nounderline abstract_t">Bhalla S, Skjei K. Fulminant vigabatrin toxicity during combination therapy with adrenocorticotropic hormone for infantile spasms: Three cases and review of the literature. Epilepsia 2020; 61:e159.</a></li><li><a class="nounderline abstract_t">Dill P, Datta AN, Weber P, Schneider J. Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms? Eur J Paediatr Neurol 2013; 17:311.</a></li><li><a class="nounderline abstract_t">Fejerman N, Cersósimo R, Caraballo R, et al. Vigabatrin as a first-choice drug in the treatment of West syndrome. J Child Neurol 2000; 15:161.</a></li><li><a class="nounderline abstract_t">Northrup H, Aronow ME, Bebin EM, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 2021; 123:50.</a></li><li><a class="nounderline abstract_t">Aicardi J, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996; 37:638.</a></li><li><a class="nounderline abstract_t">Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40:1627.</a></li><li><a class="nounderline abstract_t">Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997; 38:1270.</a></li><li><a class="nounderline abstract_t">Ohtsuka Y, Matsuda M, Ogino T, et al. Treatment of the West syndrome with high-dose pyridoxal phosphate. Brain Dev 1987; 9:418.</a></li><li><a class="nounderline abstract_t">Pietz J, Benninger C, Schäfer H, et al. Treatment of infantile spasms with high-dosage vitamin B6. Epilepsia 1993; 34:757.</a></li><li><a class="nounderline abstract_t">Vendrame M, Guilhoto LM, Loddenkemper T, et al. Outcomes of epileptic spasms in patients aged less than 3 years: single-center United States experience. Pediatr Neurol 2012; 46:276.</a></li><li><a class="nounderline abstract_t">Hussain SA, Kwong G, Millichap JJ, et al. Hypsarrhythmia assessment exhibits poor interrater reliability: a threat to clinical trial validity. Epilepsia 2015; 56:77.</a></li><li><a class="nounderline abstract_t">Takacs DS, Katyayan A, Vanderslice K, Riviello JJ. Inaccuracies in Parental Reporting of Treated Epileptic Spasms: Both Under- and Over-Reporting. Pediatr Neurol 2023; 145:119.</a></li><li><a class="nounderline abstract_t">Yuskaitis CJ, Mysak K, Godlewski B, et al. Confirmation of infantile spasms resolution by prolonged outpatient EEGs. Epilepsia Open 2021; 6:714.</a></li><li><a class="nounderline abstract_t">Lerman P, Kivity S. The efficacy of corticotropin in primary infantile spasms. J Pediatr 1982; 101:294.</a></li><li><a class="nounderline abstract_t">Singer WD, Rabe EF, Haller JS. The effect of ACTH therapy upon infantile spasms. J Pediatr 1980; 96:485.</a></li><li><a class="nounderline abstract_t">O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017; 16:33.</a></li><li><a class="nounderline abstract_t">Riikonen R. Combination therapy for treatment of infantile spasms. Lancet Neurol 2017; 16:19.</a></li><li><a class="nounderline abstract_t">Sharma S, Goel S, Kapoor D, et al. Evaluation of the Modified Atkins Diet for the Treatment of Epileptic Spasms Refractory to Hormonal Therapy: A Randomized Controlled Trial. J Child Neurol 2021; 36:686.</a></li><li><a class="nounderline abstract_t">Dressler A, Benninger F, Trimmel-Schwahofer P, et al. Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotropic hormone for infantile spasms: A single-center parallel-cohort randomized controlled trial. Epilepsia 2019; 60:441.</a></li><li><a class="nounderline abstract_t">Prezioso G, Carlone G, Zaccara G, Verrotti A. Efficacy of ketogenic diet for infantile spasms: A systematic review. Acta Neurol Scand 2018; 137:4.</a></li><li><a class="nounderline abstract_t">Shields WD, Shewmon DA, Chugani HT, Peacock WJ. Treatment of infantile spasms: medical or surgical? Epilepsia 1992; 33 Suppl 4:S26.</a></li><li><a class="nounderline abstract_t">Kramer U, Sue WC, Mikati MA. Focal features in West syndrome indicating candidacy for surgery. Pediatr Neurol 1997; 16:213.</a></li><li><a class="nounderline abstract_t">Moseley BD, Nickels K, Wirrell EC. Surgical outcomes for intractable epilepsy in children with epileptic spasms. J Child Neurol 2012; 27:713.</a></li><li><a class="nounderline abstract_t">Gettings JV, Shafi S, Boyd J, et al. The Epilepsy Surgery Experience in Children With Infantile Epileptic Spasms Syndrome at a Tertiary Care Center in Canada. J Child Neurol 2023; 38:113.</a></li><li><a class="nounderline abstract_t">Dyken PR, DuRant RH, Minden DB, King DW. Short term effects of valproate on infantile spasms. Pediatr Neurol 1985; 1:34.</a></li><li><a class="nounderline abstract_t">Bachman DS. Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982; 39:49.</a></li><li><a class="nounderline abstract_t">Pavone L, Incorpora G, La Rosa M, et al. Treatment of infantile spasms with sodium dipropylacetic acid. Dev Med Child Neurol 1981; 23:454.</a></li><li><a class="nounderline abstract_t">Barnes SE, Bower BD. Sodium valproate in the treatment of intractable childhood epilepsy. Dev Med Child Neurol 1975; 17:175.</a></li><li><a class="nounderline abstract_t">Hrachovy RA, Glaze DG, Frost JD Jr. A retrospective study of spontaneous remission and long-term outcome in patients with infantile spasms. Epilepsia 1991; 32:212.</a></li><li><a class="nounderline abstract_t">Siemes H, Spohr HL, Michael T, Nau H. Therapy of infantile spasms with valproate: results of a prospective study. Epilepsia 1988; 29:553.</a></li><li><a class="nounderline abstract_t">Fisher E, Siemes H, Pund R, et al. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity. Epilepsia 1992; 33:165.</a></li><li><a class="nounderline abstract_t">Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997; 38:1035.</a></li><li><a class="nounderline abstract_t">Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999; 21:157.</a></li><li><a class="nounderline abstract_t">Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004; 62:296.</a></li><li><a class="nounderline abstract_t">Yum SW, Zhang J, Mo K, et al. A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy. Ann Neurol 2009; 66:759.</a></li><li><a class="nounderline abstract_t">Kawawaki H, Tomiwa K, Shiraishi K, Murata R. [Efficacy of zonisamide in West syndrome]. No To Hattatsu 1999; 31:263.</a></li><li><a class="nounderline abstract_t">Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39:1324.</a></li><li><a class="nounderline abstract_t">Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000; 41 Suppl 1:S91.</a></li><li><a class="nounderline abstract_t">Weber A, Cole JW, Mytinger JR. Infantile Spasms Respond Poorly to Topiramate. Pediatr Neurol 2015; 53:130.</a></li><li><a class="nounderline abstract_t">Debus OM, Kurlemann G, Study group. Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia 2004; 45:103.</a></li><li><a class="nounderline abstract_t">Appleton RE. West syndrome: long-term prognosis and social aspects. Brain Dev 2001; 23:688.</a></li><li><a class="nounderline abstract_t">Riikonen R. Infantile Spasms: Outcome in Clinical Studies. Pediatr Neurol 2020; 108:54.</a></li><li><a class="nounderline abstract_t">Glaze DG, Hrachovy RA, Frost JD Jr, et al. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatr 1988; 112:389.</a></li><li><a class="nounderline abstract_t">Glaze DG, Zion TE. Infantile spasms. Curr Probl Pediatr 1985; 15:1.</a></li><li><a class="nounderline abstract_t">Harini C, Nagarajan E, Bergin AM, et al. Mortality in infantile spasms: A hospital-based study. Epilepsia 2020; 61:702.</a></li><li><a class="nounderline abstract_t">Riikonen R. Long-term otucome of West syndrome: a study of adults with a history of infantile spasms. Epilepsia 1996; 37:367.</a></li><li><a class="nounderline abstract_t">Gaily E, Lommi M, Lapatto R, Lehesjoki AE. Incidence and outcome of epilepsy syndromes with onset in the first year of life: A retrospective population-based study. Epilepsia 2016; 57:1594.</a></li><li class="breakAll">Lacy JR, Penry JK. Infantile spasms, Raven Press, New York 1976.</li><li><a class="nounderline abstract_t">Jeavons PM, Bower BD, Dimitrakoudi M. Long-term prognosis of 150 cases of "West syndrome". Epilepsia 1973; 14:153.</a></li><li><a class="nounderline abstract_t">JEAVONS PM, BOWER BD. The natural history of infantile spasms. Arch Dis Child 1961; 36:17.</a></li><li><a class="nounderline abstract_t">GIBBS EL, FLEMING MM, GIBBS FA. Diagnosis and prognosis of hypsarhythmia and infantile spasms. Pediatrics 1954; 13:66.</a></li><li><a class="nounderline abstract_t">Riikonen R. A long-term follow-up study of 214 children with the syndrome of infantile spasms. Neuropediatrics 1982; 13:14.</a></li><li><a class="nounderline abstract_t">Montenegro MA, Eck K, Jacob S, et al. Long-term outcome of symptomatic infantile spasms established by video-electroencephalography (EEG) monitoring. J Child Neurol 2008; 23:1288.</a></li><li><a class="nounderline abstract_t">Koo B, Hwang PA, Logan WJ. Infantile spasms: outcome and prognostic factors of cryptogenic and symptomatic groups. Neurology 1993; 43:2322.</a></li><li><a class="nounderline abstract_t">Partikian A, Mitchell WG. Neurodevelopmental and epilepsy outcomes in a North American cohort of patients with infantile spasms. J Child Neurol 2010; 25:423.</a></li><li><a class="nounderline abstract_t">Motte J, Billard C, Fejerman N, et al. Neurofibromatosis type one and West syndrome: a relatively benign association. Epilepsia 1993; 34:723.</a></li><li><a class="nounderline abstract_t">Watanabe K. West syndrome: etiological and prognostic aspects. Brain Dev 1998; 20:1.</a></li><li><a class="nounderline abstract_t">Sanmaneechai O, Sogawa Y, Silver W, et al. Treatment outcomes of West syndrome in infants with Down syndrome. Pediatr Neurol 2013; 48:42.</a></li><li><a class="nounderline abstract_t">Harvey S, Allen NM, King MD, et al. Response to treatment and outcomes of infantile spasms in Down syndrome. Dev Med Child Neurol 2022; 64:780.</a></li><li><a class="nounderline abstract_t">Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 1999; 40:286.</a></li><li><a class="nounderline abstract_t">Nelson JA, Demarest S, Thomas J, et al. Evolution of Infantile Spasms to Lennox-Gastaut Syndrome: What Is There to Know? J Child Neurol 2021; 36:752.</a></li><li><a class="nounderline abstract_t">Niedermeyer E. Lennox-Gastaut syndrome. Clinical description and diagnosis. Adv Exp Med Biol 2002; 497:61.</a></li><li><a class="nounderline abstract_t">Riikonen R. Long-term outcome of patients with West syndrome. Brain Dev 2001; 23:683.</a></li><li><a class="nounderline abstract_t">Hrachovy RA, Frost JD Jr. Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome). J Clin Neurophysiol 2003; 20:408.</a></li><li><a class="nounderline abstract_t">Matsumoto A, Watanabe K, Negoro T, et al. Long-term prognosis after infantile spasms: a statistical study of prognostic factors in 200 cases. Dev Med Child Neurol 1981; 23:51.</a></li><li><a class="nounderline abstract_t">Golomb MR, Garg BP, Williams LS. Outcomes of children with infantile spasms after perinatal stroke. Pediatr Neurol 2006; 34:291.</a></li><li><a class="nounderline abstract_t">Saemundsen E, Ludvigsson P, Rafnsson V. Risk of autism spectrum disorders after infantile spasms: a population-based study nested in a cohort with seizures in the first year of life. Epilepsia 2008; 49:1865.</a></li><li><a class="nounderline abstract_t">Lúthvígsson P, Olafsson E, Sigurthardóttir S, Hauser WA. Epidemiologic features of infantile spasms in Iceland. Epilepsia 1994; 35:802.</a></li><li><a class="nounderline abstract_t">Gaily E, Appelqvist K, Kantola-Sorsa E, et al. Cognitive deficits after cryptogenic infantile spasms with benign seizure evolution. Dev Med Child Neurol 1999; 41:660.</a></li><li><a class="nounderline abstract_t">Yuskaitis CJ, Ruzhnikov MRZ, Howell KB, et al. Infantile Spasms of Unknown Cause: Predictors of Outcome and Genotype-Phenotype Correlation. Pediatr Neurol 2018; 87:48.</a></li><li class="breakAll">Sorel L. Treatment of hypsarrhythmia with ACTH. In: Molecules and Mental Health, Gibbs FA (Ed), JB Lippincott, Philadelphia 1959.</li><li class="breakAll">Hagberg B. The nosology of epilepsy in infancy and childhood. In: Epileptic Seizures - Behavior - Pain, Birkmayer W (Ed), Huber, Bern 1976.</li><li><a class="nounderline abstract_t">Kivity S, Lerman P, Ariel R, et al. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004; 45:255.</a></li><li><a class="nounderline abstract_t">Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010; 95:382.</a></li><li><a class="nounderline abstract_t">Hamano S, Yoshinari S, Higurashi N, et al. Developmental outcomes of cryptogenic West syndrome. J Pediatr 2007; 150:295.</a></li></ol></div><div id="topicVersionRevision">Topic 6186 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35503712" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509243" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15509243" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668442" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22689735" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20608959" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Infantile spasms: a U.S. consensus report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26122601" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19435579" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15541450" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24446954" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740534" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29270989" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36600453" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36600453" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Temporal trends in the cost and use of first-line treatments for infantile epileptic spasms syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647410" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Therapeutic efficacy and adverse effects of adrenocorticotropic hormone therapy in west syndrome: differences in dosage of adrenocorticotropic hormone, onset of age, and cause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15925463" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Extremely low-dose ACTH step-up protocol for West syndrome: maximum therapeutic effect with minimal side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604274" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26704170" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Response to treatment in a prospective national infantile spasms cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701270" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : What are the reasons for the strikingly different approaches to the use of ACTH in infants with West syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084976" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effectiveness of once-daily high-dose ACTH for infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176573" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522523" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A comparative study of high-dose and low-dose ACTH therapy for West syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781414" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Low-dose ACTH therapy for West syndrome: initial effects and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980843" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : West syndrome: individualized ACTH therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8980845" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : West syndrome: individualized ACTH therapy, by Heiskala et al.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16239177" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6299719" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A prospective study of infantile spasms: clinical and therapeutic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6254450" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : ACTH therapy in infantile spasms: side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6312008" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Double-blind study of ACTH vs prednisone therapy in infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3017239" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adrenocortical hyporesponsiveness after treatment with ACTH of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381257" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174552" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Major adverse events associated with treatment of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31769329" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incidence of Hypertension Among Children Treated With Adrenocorticotropic Hormone (ACTH) or Prednisolone for Infantile Spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35759339" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adrenal insufficiency among children treated with hormonal therapy for infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35759339" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adrenal insufficiency among children treated with hormonal therapy for infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8253287" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effect of non-depot ACTH(1-24) on infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159460" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6264348" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sleep characteristics in infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/231747" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cranial computed tomography (CCT) findings in children treated with ACTH and dexamethasone: first results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6258109" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6266269" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Apparent brain atrophy and subdural hematoma following ACTH therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6290148" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : CT and ACTH treatment in infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10881271" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Subdural hematoma during low-dose ACTH therapy in patients with west syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6160427" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Interference of cortisone and ACTH with brain development? A survey of experimental studies in mice and rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/617574" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurological hazards.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21778189" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of high-dose glucocorticosteroid treatment for infantile spasms on quantitative bone parameters later in life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30564773" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31657133" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effectiveness of corticosteroids versus adrenocorticotropic hormone for infantile spasms: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31903560" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prednisolone/prednisone as adrenocorticotropic hormone alternative for infantile spasms: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35222241" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34266919" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparative Effectiveness of Initial Treatment for Infantile Spasms in a Contemporary US Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11261504" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11261501" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : How does ACTH work against infantile spasms? Bedside to bench.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11673582" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized trial of vigabatrin in patients with infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404353" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vigabatrin for the treatment of infantile spasms: final report of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12887441" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Short-term nonhormonal and nonsteroid treatment in West syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11719329" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Vigabatrin associated retinal dysfunction in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11015531" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Visual field constriction in children with epilepsy on vigabatrin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11665869" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A risk-benefit assessment of treatments for infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34716587" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Visual field defects after vigabatrin treatment during infancy: retrospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35817277" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ocular examinations, findings, and toxicity in children taking vigabatrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21070215" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19215279" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Visual fields at school-age in children treated with vigabatrin in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145415" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25381295" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18783433" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cerebral MRI abnormalities associated with vigabatrin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054414" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35180571" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Vigabatrin-associated brain abnormalities on MRI and other neurological symptoms in patients with West syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32944947" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fulminant vigabatrin toxicity during combination therapy with adrenocorticotropic hormone for infantile spasms: Three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23199677" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10757471" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Vigabatrin as a first-choice drug in the treatment of West syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34399110" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8681895" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10565592" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578521" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3434717" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of the West syndrome with high-dose pyridoxal phosphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8330589" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of infantile spasms with high-dosage vitamin B6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22520347" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Outcomes of epileptic spasms in patients aged less than 3 years: single-center United States experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25385396" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hypsarrhythmia assessment exhibits poor interrater reliability: a threat to clinical trial validity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37331271" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Inaccuracies in Parental Reporting of Treated Epileptic Spasms: Both Under- and Over-Reporting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34524734" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Confirmation of infantile spasms resolution by prolonged outpatient EEGs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6284904" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The efficacy of corticotropin in primary infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6244378" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The effect of ACTH therapy upon infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838190" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838191" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Combination therapy for treatment of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33834913" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Evaluation of the Modified Atkins Diet for the Treatment of Epileptic Spasms Refractory to Hormonal Therapy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30801699" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotropic hormone for infantile spasms: A single-center parallel-cohort randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28875525" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Efficacy of ketogenic diet for infantile spasms: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1330508" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of infantile spasms: medical or surgical?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165511" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Focal features in West syndrome indicating candidacy for surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123426" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Surgical outcomes for intractable epilepsy in children with epileptic spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36788207" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The Epilepsy Surgery Experience in Children With Infantile Epileptic Spasms Syndrome at a Tertiary Care Center in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3939740" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Short term effects of valproate on infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6275826" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of valproic acid in treatment of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6268474" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Treatment of infantile spasms with sodium dipropylacetic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1093915" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Sodium valproate in the treatment of intractable childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1848513" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A retrospective study of spontaneous remission and long-term outcome in patients with infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2842127" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Therapy of infantile spasms with valproate: results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733752" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579944" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Zonisamide monotherapy in newly diagnosed infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372900" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment of infantile spasms with zonisamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14745073" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Zonisamide treatment for symptomatic infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20039262" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10355267" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : [Efficacy of zonisamide in West syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9860068" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A pilot study of topiramate in the treatment of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768309" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Long-term response to topiramate in patients with West syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26068002" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Infantile Spasms Respond Poorly to Topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14738417" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline pyridoxine medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701278" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : West syndrome: long-term prognosis and social aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305143" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Infantile Spasms: Outcome in Clinical Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2450190" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2996835" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32133641" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Mortality in infantile spasms: A hospital-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8603642" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Long-term otucome of West syndrome: a study of adults with a history of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574005" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Incidence and outcome of epilepsy syndromes with onset in the first year of life: A retrospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574005" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Incidence and outcome of epilepsy syndromes with onset in the first year of life: A retrospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4515986" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Long-term prognosis of 150 cases of "West syndrome".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13789716" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The natural history of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13133555" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Diagnosis and prognosis of hypsarhythmia and infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6281679" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A long-term follow-up study of 214 children with the syndrome of infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984838" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Long-term outcome of symptomatic infantile spasms established by video-electroencephalography (EEG) monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232950" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Infantile spasms: outcome and prognostic factors of cryptogenic and symptomatic groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19749181" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Neurodevelopmental and epilepsy outcomes in a North American cohort of patients with infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8392464" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Neurofibromatosis type one and West syndrome: a relatively benign association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9533552" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : West syndrome: etiological and prognostic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23290019" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Treatment outcomes of West syndrome in infants with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35092693" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Response to treatment and outcomes of infantile spasms in Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080506" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33764203" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Evolution of Infantile Spasms to Lennox-Gastaut Syndrome: What Is There to Know?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11993741" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Lennox-Gastaut syndrome. Clinical description and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701277" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Long-term outcome of patients with West syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734931" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Infantile epileptic encephalopathy with hypsarrhythmia (infantile spasms/West syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6259007" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Long-term prognosis after infantile spasms: a statistical study of prognostic factors in 200 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638504" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Outcomes of children with infantile spasms after perinatal stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557779" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Risk of autism spectrum disorders after infantile spasms: a population-based study nested in a cohort with seizures in the first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082625" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Epidemiologic features of infantile spasms in Iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10587041" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Cognitive deficits after cryptogenic infantile spasms with benign seizure evolution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30174244" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Infantile Spasms of Unknown Cause: Predictors of Outcome and Genotype-Phenotype Correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30174244" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Infantile Spasms of Unknown Cause: Predictors of Outcome and Genotype-Phenotype Correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30174244" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Infantile Spasms of Unknown Cause: Predictors of Outcome and Genotype-Phenotype Correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009227" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20457702" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307550" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Developmental outcomes of cryptogenic West syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
